Related Experiment Video
Updated: May 19, 2026
11:29
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
Surgery for relapsed ovarian cancer: when should it be offered?
Philipp Harter1, Florian Heitz, Andreas du Bois
1Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Henricistr. 92, 45136, Essen, Germany. p.harter@gmx.de
Current Oncology Reports
|August 25, 2012
Summary
Cytoreductive surgery may benefit recurrent ovarian cancer if complete disease removal is achieved. Clinical scores can identify suitable patients, though high-level evidence is pending ongoing trials.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Ovarian Cancer Research
Background:
- Cytoreductive surgery is standard for primary ovarian cancer.
- The efficacy of surgery for recurrent ovarian cancer remains uncertain.
Purpose of the Study:
- To evaluate the role and potential benefit of cytoreductive surgery in recurrent ovarian cancer.
- To identify patient selection criteria for surgical intervention in recurrent disease.
Main Methods:
- Review of current treatment paradigms for recurrent ovarian cancer.
- Discussion of the potential impact of complete resection in platinum-sensitive recurrent disease.
- Mention of ongoing randomized trials (DESKTOP III, GOG 213) for Level I evidence.
Main Results:
- Complete resection of disease is a key factor for potential surgical benefit in recurrent ovarian cancer.
- Clinical scoring systems may aid in selecting appropriate candidates for surgery.
- Definitive Level I evidence is currently lacking.
Conclusions:
- Cytoreductive surgery could be a valuable option for select patients with platinum-sensitive recurrent ovarian cancer.
- Further evidence from ongoing randomized trials is crucial to establish the role of surgery.
- Patient selection is critical for optimizing outcomes in recurrent ovarian cancer surgery.
